Clinical Trial: A Study of SHR-1819 in Patients With Moderate-to-severe Atopic Dermatitis

U.S., Jan. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07321951) titled 'A Study of SHR-1819 in Patients With Moderate-to-severe Atopic Dermatitis' on Dec. 21, 2025.

Brief Summary: This trial was designed to evaluate the efficacy and safety of SHR-1819 in adult patients with moderate-to-severe atopic dermatitis.

Study Start Date: Jan., 2026

Study Type: INTERVENTIONAL

Condition: Moderate-to-severe Atopic Dermatitis

Intervention: DRUG: SHR-1819 Injection

SHR-1819 injection.

DRUG: SHR-1819 Injection Blank Preparation

SHR-1819 injection blank preparation.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd

Published by HT Digital Content Services with permissi...